The Spain Radiopharmaceuticals Market growth continues to accelerate as bone scintigraphy and palliative radionuclide therapy maintain essential roles in prostate cancer and metastatic bone disease management. With prostate cancer bone metastases representing a major source of morbidity and Technetium-99m methylene diphosphonate remaining the most widely performed nuclear medicine examination...